ProMIS Neurosciences (PMN) Guggenheim SMID Cap Biotech Conference summary

Key milestones and achievements in 2024

• Completed phase 1a clinical study in healthy volunteers, showing PMN 310 was safe and well tolerated.

• Achieved successful PIPE financing, raising nearly $123 million in a tranche structure.

• Designed and initiated a 12-month, 100-patient phase 1b study in Alzheimer's patients by year-end.

Phase 1b study design and objectives

• The 1b study aims to demonstrate safety and efficacy of PMN 310, with interim results expected in H1 2026 and final results by year-end 2026.

• Study includes three dosing cohorts (5, 10, 20 mg/kg) with DSMB oversight for safety and dose escalation.

• Enrollment is progressing rapidly across 22 activated US sites, targeting 128 patients to achieve 100 completers.

Differentiated scientific approach

• PMN 310 targets toxic amyloid beta oligomers, not plaques or monomers, aiming to avoid ARIA side effects.

• Preclinical studies showed no plaque binding and no brain hemorrhage at high doses in mice.

• The antibody’s selectivity is expected to maximize efficacy and safety compared to current therapies.